For the first time in the history of treating chronic hepatitis delta virus infection, patients have a medicine that works—and the U.S. Food and Drug Administration has approved it. Hepcludex (bulevirtide-gmod), developed by Gilead Sciences, now offers hope to adults living with this rare but serious condition that can rapidly progress to severe liver damage without treatment.
Until this moment, there has been no FDA-approved therapy for chronic hepatitis delta virus (HDV) infection. For patients navigating this disease, the absence of approved treatments has meant managing symptoms without a direct path to viral control—a stark reality that made this approval a watershed moment in hepatology. Hepatitis delta is a complex infection that only occurs in people who already have hepatitis B, making the condition doubly challenging and the therapeutic void even more profound.
The FDA's approval came through the Accelerated Approval pathway, reflecting the urgent medical need this medication addresses. Hepcludex also received Breakthrough Therapy Designation and Orphan-Drug Designation, recognizing both its therapeutic importance and the small patient population it serves. The approval was grounded in solid Phase III trial data that showed the drug's genuine effectiveness. Patients taking Hepcludex—administered as a once-daily injection at 8.5 mg for 144 weeks—showed meaningful viral suppression over time. At the 48-week mark, 20 percent of those on immediate treatment achieved undetectable HDV RNA levels (less than 50 IU/mL), compared to zero percent in the group that delayed treatment. The results improved with continued dosing: by week 96, the rate climbed to 36 percent, and by week 144, it reached 50 percent.
These numbers represent real progress against a virus that has historically offered patients little ground to stand on. Wendy Carter, D.O., from the FDA Center for Drug Evaluation and Research, captured the significance plainly: "Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available." She added that for those living with this disease, Hepcludex "offers hope in managing a disease that can rapidly progress to serious liver complications."
One important caveat bears mentioning: the medication carries a boxed warning, the FDA's strictest safety label. Discontinuing Hepcludex can trigger severe acute exacerbations of both hepatitis delta virus and hepatitis B virus infection, meaning patients will need to maintain careful adherence and medical oversight. This underscores that while this approval is genuinely transformative, it also demands a committed partnership between patients and their healthcare providers.
For individuals diagnosed with chronic hepatitis delta—particularly those without cirrhosis or with compensated cirrhosis—this approval marks a genuine turning point. What was once an untreatable diagnosis now has a path forward, backed by FDA authorization and real clinical evidence of viral suppression. As Hepcludex reaches patients through the healthcare system, it promises to reshape how this serious, progressive disease is managed, offering not just symptom relief but actual viral control.